News articles about Qiagen NV (NASDAQ:QGEN) have trended positive recently, according to AlphaOne Sentiment Analysis. AlphaOne, a unit of Accern, identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real-time. AlphaOne ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Qiagen NV earned a news impact score of 0.37 on AlphaOne’s scale. AlphaOne also assigned media headlines about the company an impact score of 69 out of 100, indicating that recent news coverage is likely to have an impact on the stock’s share price in the near term.
Qiagen NV (NASDAQ:QGEN) traded down 0.24% on Friday, hitting $32.76. 188,835 shares of the company traded hands. The stock’s 50-day moving average is $30.50 and its 200 day moving average is $29.36. Qiagen NV has a 12 month low of $20.71 and a 12 month high of $32.97. The firm has a market capitalization of $7.46 billion, a P/E ratio of 91.00 and a beta of 1.05.
Several equities research analysts have recently commented on QGEN shares. Deutsche Bank AG restated a “buy” rating on shares of Qiagen NV in a report on Monday, January 30th. Jefferies Group LLC restated a “hold” rating on shares of Qiagen NV in a report on Friday, February 3rd. Commerzbank Ag restated a “buy” rating on shares of Qiagen NV in a report on Friday, February 3rd. DZ Bank AG restated a “neutral” rating on shares of Qiagen NV in a report on Monday, February 6th. Finally, Zacks Investment Research upgraded shares of Qiagen NV from a “sell” rating to a “hold” rating in a report on Friday, March 17th. Seven analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Qiagen NV currently has a consensus rating of “Hold” and an average price target of $28.36.
About Qiagen NV
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen NV and related companies with our FREE daily email newsletter.